Related Experiment Video

Updated: Jun 10, 2026

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

Management of hereditary angioedema: 2010 Canadian approach

Tom Bowen1, John Brosz, Kristylea Brosz

  • 1Canadian Hereditary Angioedema Network (CHAEN)/Réseau Canadien d'Angioédème Héréditaire (RCAH), 705 South Tower, 3031 Hospital Dr, NW Calgary, Alberta, Canada. tbowen@pol.net.

Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
|July 30, 2010
PubMed

Insights

C1-inhibitor (C1-INH) deficiency causes hereditary angioedema (HAE) attacks. This review details updated Canadian management strategies for HAE, reflecting advancements in prophylaxis and therapy.

Area of Science:

  • Hematology
  • Immunology
  • Genetics

Background:

  • C1-inhibitor (C1-INH) deficiency is a rare genetic disorder.
  • It leads to hereditary angioedema (HAE) attacks, which can be severe and life-threatening.
  • Patient care and management have evolved significantly.

Purpose of the Study:

  • To present a comprehensive review of HAE management in Canada.
  • To highlight advancements in diagnosis, therapy, and prophylaxis.
  • To support the Canadian Hereditary Angioedema Network (CHAEN) in improving patient care.

Main Methods:

  • Review of current literature and clinical practices in Canada.
  • Analysis of changes in HAE management since the first Canadian Consensus Conference.
  • Formation of the Canadian Hereditary Angioedema Network (CHAEN) to advance patient care.

Main Results:

  • Significant changes in prophylaxis and therapy protocols for HAE.
  • Establishment of a national network (CHAEN) to coordinate and improve HAE care.
  • Updated consensus on the diagnosis, therapy, and management of HAE in Canada.

Conclusions:

  • HAE management in Canada has advanced considerably.
  • The CHAEN network is crucial for continued improvement in patient outcomes.
  • Ongoing review and updates are essential for optimal HAE care.

Related Concept Videos

Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Angina V: Nursing Management01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...